TY - CHAP AU - Jemal, A. AU - Siegel, R. AU - Xu, J. AU - Ward, E. PY - 2010 DA - 2010// TI - Cancer Statistics BT - CA: a cancer journal for clinicians ID - Jemal2010 ER - TY - JOUR AU - Petrelli, N. J. AU - Winer, E. P. AU - Brahmer, J. AU - Dubey, S. AU - Smith, S. AU - Thomas, C. AU - Vahdat, L. T. AU - Obel, J. AU - Vogelzang, N. AU - Markman, M. PY - 2009 DA - 2009// TI - Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.26.6171 DO - 10.1200/JCO.2009.26.6171 ID - Petrelli2009 ER - TY - STD TI - Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M: Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 (Suppl 5): v15-19. ID - ref3 ER - TY - STD TI - Andreetta C, Minisini AM, Miscoria M, Puglisi F: First-line chemotherapy with or without biologic agents for metastatic breast cancer. Crit Rev Oncol Hematol. 76 (2): 99-111. ID - ref4 ER - TY - JOUR AU - Andreopoulou, E. AU - Hortobagyi, G. N. PY - 2008 DA - 2008// TI - Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.16.1026 DO - 10.1200/JCO.2008.16.1026 ID - Andreopoulou2008 ER - TY - JOUR AU - Guarneri, V. AU - Conte, P. PY - 2009 DA - 2009// TI - Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy JO - The oncologist VL - 14 UR - https://doi.org/10.1634/theoncologist.2009-0078 DO - 10.1634/theoncologist.2009-0078 ID - Guarneri2009 ER - TY - JOUR AU - Hicklin, D. J. AU - Ellis, L. M. PY - 2005 DA - 2005// TI - Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.06.081 DO - 10.1200/JCO.2005.06.081 ID - Hicklin2005 ER - TY - JOUR AU - Konecny, G. E. AU - Meng, Y. G. AU - Untch, M. AU - Wang, H. J. AU - Bauerfeind, I. AU - Epstein, M. AU - Stieber, P. AU - Vernes, J. M. AU - Gutierrez, J. AU - Hong, K. PY - 2004 DA - 2004// TI - Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-0951-3 DO - 10.1158/1078-0432.CCR-0951-3 ID - Konecny2004 ER - TY - JOUR AU - Sledge, G. W. PY - 2002 DA - 2002// TI - Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects JO - Semin Oncol VL - 29 UR - https://doi.org/10.1053/sonc.2002.34062 DO - 10.1053/sonc.2002.34062 ID - Sledge2002 ER - TY - JOUR AU - de Castro Junior, G. AU - Puglisi, F. AU - de Azambuja, E. AU - El Saghir, N. S. AU - Awada, A. PY - 2006 DA - 2006// TI - Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm) JO - Crit Rev Oncol Hematol VL - 59 UR - https://doi.org/10.1016/j.critrevonc.2006.02.007 DO - 10.1016/j.critrevonc.2006.02.007 ID - de Castro Junior2006 ER - TY - JOUR AU - Jain, R. K. PY - 2001 DA - 2001// TI - Clearing the smoke on nicotine and angiogenesis JO - Nat Med VL - 7 UR - https://doi.org/10.1038/89889 DO - 10.1038/89889 ID - Jain2001 ER - TY - JOUR AU - Gasparini, G. AU - Longo, R. AU - Fanelli, M. AU - Teicher, B. A. PY - 2005 DA - 2005// TI - Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.10.022 DO - 10.1200/JCO.2005.10.022 ID - Gasparini2005 ER - TY - JOUR AU - Gray, R. AU - Bhattacharya, S. AU - Bowden, C. AU - Miller, K. AU - Comis, R. L. PY - 2009 DA - 2009// TI - Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.6630 DO - 10.1200/JCO.2008.21.6630 ID - Gray2009 ER - TY - CHAP AU - Miles, D. W. AU - Chan, A. AU - Dirix, L. Y. AU - Cortes, J. AU - Pivot, X. AU - Tomczak, P. AU - Delozier, T. AU - Sohn, J. H. AU - Provencher, L. AU - Puglisi, F. PY - 2011 DA - 2011// TI - Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer BT - J Clin Oncol ID - Miles2011 ER - TY - JOUR AU - Miller, K. AU - Wang, M. AU - Gralow, J. AU - Dickler, M. AU - Cobleigh, M. AU - Perez, E. A. AU - Shenkier, T. AU - Cella, D. AU - Davidson, N. E. PY - 2007 DA - 2007// TI - Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer JO - The New England journal of medicine VL - 357 UR - https://doi.org/10.1056/NEJMoa072113 DO - 10.1056/NEJMoa072113 ID - Miller2007 ER - TY - JOUR AU - Robert, N. J. AU - Dieras, V. AU - Glaspy, J. AU - Brufsky, A. AU - Bondarenko, I. AU - Lipatov, O. AU - Perez, E. AU - Yardley, D. AU - Zhou, X. AU - Phan, S. PY - 2009 DA - 2009// TI - RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) JO - J Clin Oncol (Meeting Abstracts) VL - 27 ID - Robert2009 ER - TY - JOUR AU - Pignon, J. P. AU - Hill, C. PY - 2001 DA - 2001// TI - Meta-analyses of randomised clinical trials in oncology JO - The lancet oncology VL - 2 UR - https://doi.org/10.1016/S1470-2045(01)00453-3 DO - 10.1016/S1470-2045(01)00453-3 ID - Pignon2001 ER - TY - JOUR AU - Bria, E. AU - Milella, M. AU - Gelibter, A. AU - Cuppone, F. AU - Pino, M. S. AU - Ruggeri, E. M. AU - Carlini, P. AU - Nistico, C. AU - Terzoli, E. AU - Cognetti, F. PY - 2007 DA - 2007// TI - Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?: a meta-analysis of 20 phase 3 trials JO - Cancer VL - 110 UR - https://doi.org/10.1002/cncr.22809 DO - 10.1002/cncr.22809 ID - Bria2007 ER - TY - JOUR AU - Parmar, M. K. AU - Torri, V. AU - Stewart, L. PY - 1998 DA - 1998// TI - Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints JO - Statistics in medicine VL - 17 UR - https://doi.org/3.0.CO;2-8 DO - 3.0.CO;2-8 ID - Parmar1998 ER - TY - JOUR AU - Tierney, J. F. AU - Stewart, L. A. AU - Ghersi, D. AU - Burdett, S. AU - Sydes, M. R. PY - 2007 DA - 2007// TI - Practical methods for incorporating summary time-to-event data into meta-analysis JO - Trials VL - 8 UR - https://doi.org/10.1186/1745-6215-8-16 DO - 10.1186/1745-6215-8-16 ID - Tierney2007 ER - TY - CHAP AU - Higgins, J. P. T. AU - Green, S. PY - 2006 DA - 2006// TI - Cochrane handbook for Systematic Reviews of intervention 4.2.6 [updated sep 2006] BT - The Cochrane Library PB - Sons, Ltd CY - Chichester, UK ID - Higgins2006 ER - TY - JOUR AU - Case, L. D. AU - Kimmick, G. AU - Paskett, E. D. AU - Lohman, K. AU - Tucker, R. PY - 2002 DA - 2002// TI - Interpreting measures of treatment effect in cancer clinical trials JO - The oncologist VL - 7 UR - https://doi.org/10.1634/theoncologist.7-3-181 DO - 10.1634/theoncologist.7-3-181 ID - Case2002 ER - TY - JOUR AU - Bria, E. AU - Gralla, R. J. AU - Raftopoulos, H. AU - Cuppone, F. AU - Milella, M. AU - Sperduti, I. AU - Carlini, P. AU - Terzoli, E. AU - Cognetti, F. AU - Giannarelli, D. PY - 2008 DA - 2008// TI - Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials JO - Lung Cancer VL - 63 UR - https://doi.org/10.1016/j.lungcan.2008.05.002 DO - 10.1016/j.lungcan.2008.05.002 ID - Bria2008 ER - TY - CHAP AU - Parmar, M. K. B. AU - Machin, D. PY - 1995 DA - 1995// BT - Survival analysis: a practical approach PB - John Wiley CY - Chichester (England) ID - Parmar1995 ER - TY - JOUR AU - Altman, D. G. PY - 1998 DA - 1998// TI - Confidence intervals for the number needed to treat JO - BMJ (Clinical research ed VL - 317 UR - https://doi.org/10.1136/bmj.317.7168.1309 DO - 10.1136/bmj.317.7168.1309 ID - Altman1998 ER - TY - JOUR AU - Brufsky, A. AU - Bondarenko, I. AU - Smirnov, V. AU - Hurvitz, S. AU - Perez, E. AU - Ponomarova, O. AU - Vynnychenko, I. AU - Swamy, R. AU - Mu, H. AU - Rivera, R. PY - 2009 DA - 2009// TI - RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.SABCS-09-42 DO - 10.1158/0008-5472.SABCS-09-42 ID - Brufsky2009 ER - TY - JOUR AU - Miller, K. D. AU - Chap, L. I. AU - Holmes, F. A. AU - Cobleigh, M. A. AU - Marcom, P. K. AU - Fehrenbacher, L. AU - Dickler, M. AU - Overmoyer, B. A. AU - Reimann, J. D. AU - Sing, A. P. PY - 2005 DA - 2005// TI - Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.05.098 DO - 10.1200/JCO.2005.05.098 ID - Miller2005 ER - TY - JOUR AU - Albain, K. S. AU - Nag, S. M. AU - Calderillo-Ruiz, G. AU - Jordaan, J. P. AU - Llombart, A. C. AU - Pluzanska, A. AU - Rolski, J. AU - Melemed, A. S. AU - Reyes-Vidal, J. M. AU - Sekhon, J. S. PY - 2008 DA - 2008// TI - Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.11.9362 DO - 10.1200/JCO.2007.11.9362 ID - Albain2008 ER - TY - JOUR AU - O'Shaughnessy, J. AU - Miles, D. AU - Vukelja, S. AU - Moiseyenko, V. AU - Ayoub, J. P. AU - Cervantes, G. AU - Fumoleau, P. AU - Jones, S. AU - Lui, W. Y. AU - Mauriac, L. PY - 2002 DA - 2002// TI - Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.09.002 DO - 10.1200/JCO.2002.09.002 ID - O'Shaughnessy2002 ER - TY - JOUR AU - Piccart-Gebhart, M. J. AU - Burzykowski, T. AU - Buyse, M. AU - Sledge, G. AU - Carmichael, J. AU - Luck, H. J. AU - Mackey, J. R. AU - Nabholtz, J. M. AU - Paridaens, R. AU - Biganzoli, L. PY - 2008 DA - 2008// TI - Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.10.8399 DO - 10.1200/JCO.2007.10.8399 ID - Piccart-Gebhart2008 ER - TY - JOUR AU - Broglio, K. R. AU - Berry, D. A. PY - 2009 DA - 2009// TI - Detecting an overall survival benefit that is derived from progression-free survival JO - J Natl Cancer Inst VL - 101 UR - https://doi.org/10.1093/jnci/djp369 DO - 10.1093/jnci/djp369 ID - Broglio2009 ER - TY - JOUR AU - Lee, J. B. AU - Woo, O. H. AU - Park, K. H. AU - Woo, S. U. AU - Yang, D. S. AU - Kim, A. R. AU - Lee, E. S. AU - Kim, Y. H. AU - Kim, J. S. AU - Seo, J. H. PY - 2009 DA - 2009// TI - Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials JO - Invest New Drugs VL - 29 UR - https://doi.org/10.1007/s10637-009-9310-0 DO - 10.1007/s10637-009-9310-0 ID - Lee2009 ER - TY - STD TI - Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D: Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 122 (1): 1-7. ID - ref33 ER - TY - CHAP AU - Miles, D. W. AU - Romieu, G. AU - Dieras, V. AU - Chen, D. AU - Duenne, A. AU - Robert, N. PY - 2010 DA - 2010// TI - Meta-analysis of patients (PTS) 65 years from three Randomized trials of Bevacizumab (BV) and first-line Chemotherapy as treatment for Metastatic Breast Cancer (MBC) BT - European Society for Medical Oncology (ESMO): 2010; Milan (ITALY) ID - Miles2010 ER - TY - CHAP AU - Miles, D. W. AU - Romieu, G. AU - Dieras, V. AU - Chen, D. AU - Duenne, A. AU - O'Shaughnessy, J. PY - 2010 DA - 2010// TI - Meta-analysis of patients (PTS) previously treated with Taxanes from three Randomized trials of Bevacizumab (BV) and first-line Chemotherapy as treatment for Metastatic Breast Cancer (MBC) BT - European Society for Medical Oncology (ESMO): 2010; Milan (ITALY) ID - Miles2010 ER - TY - JOUR AU - Straus, S. E. PY - 2002 DA - 2002// TI - Individualizing treatment decisions. The likelihood of being helped or harmed JO - Evaluation & the health professions VL - 25 UR - https://doi.org/10.1177/016327870202500206 DO - 10.1177/016327870202500206 ID - Straus2002 ER - TY - JOUR AU - Barrios, C. AU - Liu, M. AU - Lee, S. AU - Vanlemmens, L. AU - Ferrero, J. AU - Tabei, T. AU - Pivot, X. AU - Iwata, H. AU - Aogi, K. AU - Brickman, M. PY - 2009 DA - 2009// TI - Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC) JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.SABCS-09-46 DO - 10.1158/0008-5472.SABCS-09-46 ID - Barrios2009 ER - TY - JOUR AU - Baselga, J. AU - Roche, H. AU - Costa, F. AU - Getulio Martins Segalla, J. AU - Pinczowski, H. AU - Ma Ciruelos, E. AU - Cabral Filho, S. AU - Gomez, P. AU - Van Eyll, B. PY - 2009 DA - 2009// TI - SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC) JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.SABCS-09-45 DO - 10.1158/0008-5472.SABCS-09-45 ID - Baselga2009 ER - TY - JOUR AU - Gradishar, W. AU - Kaklamani, V. AU - Prasad Sahoo, T. AU - Lokanatha, D. AU - Raina, V. AU - Bondarde, S. AU - Jain, M. PY - 2009 DA - 2009// TI - A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC) JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.SABCS-09-44 DO - 10.1158/0008-5472.SABCS-09-44 ID - Gradishar2009 ER - TY - JOUR AU - Mackey, J. AU - Hurvitz, S. AU - Crown, J. AU - Forbes, J. AU - Roche, H. AU - Pinter, T. AU - Eiermann, W. AU - Kennedy, M. AU - Priou, F. AU - Provencher, L. PY - 2009 DA - 2009// TI - CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC) JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.SABCS-09-47 DO - 10.1158/0008-5472.SABCS-09-47 ID - Mackey2009 ER - TY - STD TI - Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA: Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 29 (6): 632-638. ID - ref41 ER - TY - STD TI - Ranpura V, Hapani S, Wu S: Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. Jama. 305 (5): 487-494. ID - ref42 ER - TY - STD TI - Verma N, Swain SM: Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?. J Clin Oncol. 29 (6): 603-606. ID - ref43 ER - TY - STD TI - Hayes DF: Bevacizumab treatment for solid tumors: boon or bust?. Jama. 305 (5): 506-508. ID - ref44 ER -